Cardiac Safety with High Cumulative Dose of Pegylated Liposomal Doxorubicin in Patients with Metastatic Breast Cancer Previously Treated with Conventional Anthracyclines

Journals Menu

Follow SCIRP

ISSN Print: 2168-1589
ISSN Online: 2168-1597
www.scirp.org/journal/abcr
E-mail: abcr@scirp.org

Citations

"Cardiac Safety with High Cumulative Dose of Pegylated Liposomal Doxorubicin in Patients with Metastatic Breast Cancer Previously Treated with Conventional Anthracyclines"
written by Ahmed Refaat, Dalia O. Mohamed, Elsayed Mostafa Ali, Salah Mabrouk Khallaf,
published by Advances in Breast Cancer Research, Vol.9 No.3, 2020

has been cited by the following article(s):

[1]	Cardiac Safety of Pegylated Liposomal Doxorubicin After Conventional Doxorubicin Exposure in Patients With Sarcoma and Breast Cancer
	Cureus, 2023

Follow SCIRP

[1]	Doxorubicin or Epirubicin Versus Liposomal Doxorubicin Therapy—Differences in Cardiotoxicity Cardiovascular Toxicology, 2025 DOI:10.1007/s12012-024-09952-4

[2]	Cardiac Safety of Pegylated Liposomal Doxorubicin After Conventional Doxorubicin Exposure in Patients With Sarcoma and Breast Cancer Cureus, 2023 DOI:10.7759/cureus.44837